Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry
Objective Biologic therapies have revolutionized the management of moderate-to-severe psoriasis; however, there are a limited number of US real-world studies characterizing patients based on response to these treatments. This study examined characteristics at enrollment and change in outcomes of US...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-11-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2020.1720586 |
| _version_ | 1797683613296230400 |
|---|---|
| author | Abby S. Van Voorhees Marc A. Mason Leslie R. Harrold Ning Guo Adriana Guana Haijun Tian Vivian Herrera Bruce E. Strober |
| author_facet | Abby S. Van Voorhees Marc A. Mason Leslie R. Harrold Ning Guo Adriana Guana Haijun Tian Vivian Herrera Bruce E. Strober |
| author_sort | Abby S. Van Voorhees |
| collection | DOAJ |
| description | Objective Biologic therapies have revolutionized the management of moderate-to-severe psoriasis; however, there are a limited number of US real-world studies characterizing patients based on response to these treatments. This study examined characteristics at enrollment and change in outcomes of US patients with moderate-to-severe psoriasis who achieved insufficient responses with ustekinumab. Methods This study included patients enrolled in the Corrona Psoriasis Registry from April 2015 to June 2018 who initiated ustekinumab at enrollment and who were stratified based on achievement of psoriasis body surface area improving to <3% or by 75% from enrollment to the 6-month follow-up visit (response vs insufficient response). Patient demographics and disease characteristics were described at enrollment, and changes in outcomes were assessed at 6-month follow-up for ustekinumab responders and insufficient responders. Results Of the 178 patients who initiated ustekinumab in the Corrona Psoriasis Registry and had ≥1 follow-up visit, 99 (55.6%) were classified as responders at the 6-month follow-up visit. Logistic regression modeling showed that increasing age was significantly associated with a decreased likelihood of achieving a response (OR, 0.981 [95%CI, 0.962–0.999]; p = .049). Conclusions These findings may help dermatologists characterize patients with moderate-to-severe psoriasis who have inadequate responses to biologic treatments. |
| first_indexed | 2024-03-12T00:17:02Z |
| format | Article |
| id | doaj.art-6d3235af1b564c508b22ad709fe54d8b |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:17:02Z |
| publishDate | 2021-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-6d3235af1b564c508b22ad709fe54d8b2023-09-15T14:23:05ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532021-11-0132890791510.1080/09546634.2020.17205861720586Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis RegistryAbby S. Van Voorhees0Marc A. Mason1Leslie R. Harrold2Ning Guo3Adriana Guana4Haijun Tian5Vivian Herrera6Bruce E. Strober7Eastern Virginia Medical SchoolCorrona, LLCCorrona, LLCCorrona, LLCNovartis Pharmaceuticals CorporationNovartis Pharmaceuticals CorporationNovartis Pharmaceuticals CorporationUniversity of Connecticut Health CenterObjective Biologic therapies have revolutionized the management of moderate-to-severe psoriasis; however, there are a limited number of US real-world studies characterizing patients based on response to these treatments. This study examined characteristics at enrollment and change in outcomes of US patients with moderate-to-severe psoriasis who achieved insufficient responses with ustekinumab. Methods This study included patients enrolled in the Corrona Psoriasis Registry from April 2015 to June 2018 who initiated ustekinumab at enrollment and who were stratified based on achievement of psoriasis body surface area improving to <3% or by 75% from enrollment to the 6-month follow-up visit (response vs insufficient response). Patient demographics and disease characteristics were described at enrollment, and changes in outcomes were assessed at 6-month follow-up for ustekinumab responders and insufficient responders. Results Of the 178 patients who initiated ustekinumab in the Corrona Psoriasis Registry and had ≥1 follow-up visit, 99 (55.6%) were classified as responders at the 6-month follow-up visit. Logistic regression modeling showed that increasing age was significantly associated with a decreased likelihood of achieving a response (OR, 0.981 [95%CI, 0.962–0.999]; p = .049). Conclusions These findings may help dermatologists characterize patients with moderate-to-severe psoriasis who have inadequate responses to biologic treatments.http://dx.doi.org/10.1080/09546634.2020.1720586psoriasiscorrona psoriasis registryeffectivenessustekinumab |
| spellingShingle | Abby S. Van Voorhees Marc A. Mason Leslie R. Harrold Ning Guo Adriana Guana Haijun Tian Vivian Herrera Bruce E. Strober Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry Journal of Dermatological Treatment psoriasis corrona psoriasis registry effectiveness ustekinumab |
| title | Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry |
| title_full | Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry |
| title_fullStr | Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry |
| title_full_unstemmed | Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry |
| title_short | Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry |
| title_sort | characterization of insufficient responders to ustekinumab in patients with moderate to severe psoriasis in the us corrona psoriasis registry |
| topic | psoriasis corrona psoriasis registry effectiveness ustekinumab |
| url | http://dx.doi.org/10.1080/09546634.2020.1720586 |
| work_keys_str_mv | AT abbysvanvoorhees characterizationofinsufficientresponderstoustekinumabinpatientswithmoderatetoseverepsoriasisintheuscorronapsoriasisregistry AT marcamason characterizationofinsufficientresponderstoustekinumabinpatientswithmoderatetoseverepsoriasisintheuscorronapsoriasisregistry AT leslierharrold characterizationofinsufficientresponderstoustekinumabinpatientswithmoderatetoseverepsoriasisintheuscorronapsoriasisregistry AT ningguo characterizationofinsufficientresponderstoustekinumabinpatientswithmoderatetoseverepsoriasisintheuscorronapsoriasisregistry AT adrianaguana characterizationofinsufficientresponderstoustekinumabinpatientswithmoderatetoseverepsoriasisintheuscorronapsoriasisregistry AT haijuntian characterizationofinsufficientresponderstoustekinumabinpatientswithmoderatetoseverepsoriasisintheuscorronapsoriasisregistry AT vivianherrera characterizationofinsufficientresponderstoustekinumabinpatientswithmoderatetoseverepsoriasisintheuscorronapsoriasisregistry AT bruceestrober characterizationofinsufficientresponderstoustekinumabinpatientswithmoderatetoseverepsoriasisintheuscorronapsoriasisregistry |